Active Ingredient History
Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment. It is a human monoclonal antibody that belongs to a novel class of anti-cholesterol drugs, known as PCSK9 inhibitors, and it was the first such agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 4)
Alcohol Drinking (Phase 1)
Alcohol-Induced Disorders (Phase 1)
Anemia, Aplastic (Phase 1/Phase 2)
Angina Pectoris (Phase 4)
Aortic Valve Stenosis (Phase 3)
Atherosclerosis (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cardiovascular Diseases (Phase 3)
Constriction, Pathologic (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Circulation (Phase 3)
Coronary Disease (Phase 1)
Coronary Vessels (Phase 3)
Diabetes Mellitus, Type 2 (Phase 3)
Dyslipidemias (Phase 4)
Healthy Volunteers (Phase 1)
Hemorrhage (Early Phase 1)
HIV Infections (Phase 3)
Homozygous Familial Hypercholesterolemia (Phase 4)
Hypercholesterolemia (Phase 4)
Hyperlipidemias (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Inflammation (Phase 4)
Intracranial Arteriosclerosis (Phase 3)
Ischemic Stroke (Phase 4)
Livedoid Vasculopathy (Phase 4)
Myocardial Infarction (Phase 4)
Myocardium (Phase 3)
Peripheral Arterial Disease (Phase 4)
Peritoneal Dialysis (Phase 3)
Pharmacokinetics (Phase 1)
Physiological Effects of Drugs (Phase 2)
Plaque, Atherosclerotic (Phase 3)
Renal Dialysis (Phase 3)
Sepsis (Phase 2/Phase 3)
Shock, Septic (Phase 2/Phase 3)
ST Elevation Myocardial Infarction (Phase 2)
Stroke (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
